Ubiquigent Ltd announces significant expansion of its DUBprofiler™ compound selectivity service enabling the profiling of drug lead compounds versus 35 deubiquitylase enzymes.
*Dundee, UK, 27th November 2012 - Ubiquigent Ltd. today announced the significant expansion of their DUBprofiler service compound profiling panel from 23 to 35 deubiquitylase enzymes (44% of the predicted number of DUBs). The Ubiquigent DUBprofiler service delivers to clients critical information regarding the selectivity and potency of their deubiquitylase (DUB) drug discovery programme compounds. Further the DUBprofiler* service provides Ubiquigent's clients with maximum profiling flexibility - any number of compounds may be activity profiled against any combination of DUBs in single point or IC50 profiling mode.
Ubiquigent have also developed DUBprofiler-HT (high-throughput) for clients wishing to screen larger numbers of compounds in one profiling experiment; for example for screening sub-libraries such as high diversity or DUB-focussed libraries. Compound submission is very straightforward and Ubiquigent offers a two-week profiling service cycle.
For Ubiquigent contact details click here
Ubiquigent Limited is a specialist developer and supplier of high quality reagents, kits and drug discovery assay development and compound profiling services to the life science research community worldwide. Ubiquigent's scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.